Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
1 competitor in Metastatic Merkel Cell Carcinoma
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Zynyz
Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy
View on EMAZynyz
Squamous cell carcinoma of the anal canal (SCAC) Zynyz is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). Merkel cell carcinoma (MCC) Zynyz is indicated as monotherapy for the first line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) not amenable to curative surgery or radiation therapy.